Work

A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.tps5091

Authors: Michael J. Morris, Ronald De Wit, Nicholas J. Vogelzang, Scott T. Tagawa, Celestia S. Higano, Paul Hamberg

Institutions: Memorial Sloan Kettering Cancer Center, Erasmus MC Cancer Institute, Comprehensive Cancer Centers of Nevada, Weill Cornell Medicine, Fred Hutch Cancer Center, Sint Franciscus Gasthuis

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4253496486

Cites:

Cited by: 7

Related to: 10